Biosimilar Therapy Shows Equal 6-Month Remission Rates in AAV
Six-month remission rates with biosimilar versions of rituximab are comparable to those seen with the original therapy in adults with granulomatosis with polyangiitis and microscopic polyangiitis, according to a real-world multicenter cohort study published in ACR Open Rheumatology. Real-World Canadian Study Tracks Outcomes Across Treatment Groups The study, titled “Biosimilar Rituximab in ANCA-Associated Vasculitis Compared … Read more